BRIEF published on 09/21/2026 at 19:05, 10 days 17 hours ago MaaT Pharma Advances MaaT034 for Clinical Trials in Solid Tumors Clinical Trials Solid Tumors MaaT Pharma FDA Meeting MaaT034
PRESS RELEASE published on 09/21/2026 at 19:00, 10 days 17 hours ago Inside Information / Other news releases MaaT Pharma announces Pre-IND meeting with FDA for MaaT034 clinical development in solid tumors. Company advances microbiome therapies for cancer patients through immune modulation FDA MaaT Pharma Pre-IND Meeting MaaT034 Microbiome Therapies
BRIEF published on 09/18/2026 at 07:35, 14 days 5 hours ago MaaT Pharma Faces Setback with CHMP Decision on MaaT013 Clinical Trial MaaT013 CHMP Decision PHOENIX Study Regulatory Plan
PRESS RELEASE published on 09/18/2026 at 07:30, 14 days 5 hours ago Inside Information / Other news releases MaaT Pharma provides update on CHMP negative opinion for MaaT013 (Xervyteg) development plan, focusing on Phase 3 trial PHOENIX. FDA support noted for potential patient enrollment in H1 2027 FDA Phase 3 Trial MaaT Pharma CHMP MaaT013
BRIEF published on 09/15/2026 at 07:35, 17 days 5 hours ago MaaT Pharma: unfavorable vote by the CHMP for MaaT013 MaaT Pharma MaaT013 CHAMP Negative Vote Randomized Trial
PRESS RELEASE published on 09/15/2026 at 07:30, 17 days 5 hours ago Inside Information / Other news releases MaaT Pharma receives negative CHMP trend vote for MaaT013 (Xervyteg) conditional marketing authorization application in Europe. Company vows to explore options for patient access MaaT Pharma CHMP Clinical Benefit Xervyteg Negative Trend
BRIEF published on 07/24/2026 at 12:17, 2 months 9 days ago Invus Public Equities reduces its stake in MAAT PHARMA Voting Rights Threshold Crossing Transfer Of Shares MaaT Pharma Invus
BRIEF published on 07/02/2026 at 18:35, 2 months 30 days ago Current status of MaaT Pharma shares and voting rights Euronext Paris Voting Rights Biotechnology Actions MaaT Pharma
BRIEF published on 06/30/2026 at 13:13, 3 months 1 day ago MaaT Pharma's Marketing Application for MaaT013 Faces Setback Graft-versus-Host Disease MaaT Pharma CHMP Decision Marketing Application Re-examination Appeal
PRESS RELEASE published on 06/30/2026 at 13:08, 3 months 1 day ago Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Under review First Berlin Equity Research updates rating and price target for MaaT Pharma SACA after CHMP's negative opinion on MAA for MaaT013 in aGvHD First Berlin Equity Research CHMP AGvHD MaaT Pharma SACA MAA
Published on 10/02/2026 at 00:30, 12 hours 7 minutes ago Immutable Holdings Provides Corporate Update
Published on 10/01/2026 at 23:05, 13 hours 32 minutes ago Vox Royalty Expands Revolving Credit Facility Up to $150 Million and Strengthens Leadership Team
Published on 10/01/2026 at 22:00, 14 hours 37 minutes ago Golden Minerals Company Announces New Management Appointments and Resignation of Mr. Pablo Castanos
Published on 10/02/2026 at 11:35, 1 hour 2 minutes ago One in Three: As Europe Goes Electric, VinFast Builds for the Long Term
Published on 10/02/2026 at 11:19, 1 hour 18 minutes ago Custodian Property Income REIT plc: Director Declaration
Published on 10/02/2026 at 10:15, 2 hours 22 minutes ago Tennor Global takes 65% stake in Alpha Energy's new international arm
Published on 10/01/2026 at 19:00, 17 hours 37 minutes ago AMA CORP PLC reduces its cost base while preserving XpertEye’s key functions
Published on 10/01/2026 at 18:40, 17 hours 57 minutes ago Monthly disclosure of the total number of shares and voting rights - September 2026
Published on 10/01/2026 at 18:05, 18 hours 32 minutes ago Covivio - Information on total number of voting rights and share capital
Published on 10/01/2026 at 18:00, 18 hours 37 minutes ago Saint-Gobain completes the acquisition of Xypex (North America), a leader in high value-added waterproofing solutions
Published on 10/01/2026 at 17:55, 18 hours 42 minutes ago Disclosure of transactions in own shares from September 28 to September 30, 2026
